SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

CATX

Perspective Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7d 6h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor upcoming End-of-Phase 2 meeting with FDA for bamzireotide in NETs (targeted 1Q 2027) and further clinical data readouts for VMT01 and PSV359 in 2027. Cash runway into 2028 reduces near-term financing risk.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

CATX drug pipeline →

bamzireotide

◆ Mixed Named in this press release
Impact
Phase
Phase 1/2a
Time to market
At least 3-5 years, assuming a successful End-of-Phase 2 meeting in Q1 2027, a Phase 3 trial initiated in 2027, positive readout, and subsequent FDA filing and review.
Next catalyst
None dated

What to watchWatch for the End-of-Phase 2 meeting outcome with the FDA in Q1 2027, which will determine the Phase 3 trial design and registration path. Positive FDA alignment could re-rate the stock from its deeply depressed levels, while negative feedback or a delayed timeline would add to the execution risks flagged by RBC. The company's ~$100M market cap and likely need for financing to fund a Phase 3 trial create additional overhang.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$0.7864
T+0 close · Nov 9, 2026 · via day close
Latest settled
+4.93%
T+1 · $0.8252
Vs SPY
+3.62%
α at T+1
Next horizon
T+5
in 8h
  1. T+0 · Nov 10 $0.7864entry
  2. T+1 · 6d ago +4.93%α +3.62% · $0.8252
  3. T+4 · todayOpen
  4. T+5 · in 8h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Perspective Therapeutics reported a Q3 2026 net loss of $32.4M ($0.27 per share), wider than the $26.0M loss in Q3 2025, on minimal grant revenue of $20K. Cash and short-term investments rose to $202M, sufficient to fund operations into 2028. The press release highlights clinical progress across three radiopharmaceutical programs and a Fast Track designation for PSV359, but no revenue or EPS consensus beat/miss can be determined as the company is pre-revenue.

Key Financial Metrics

EPS
−$0.27
Revenue
$20.0K
est $48.0K · -58.3% · -90.4% YoY

Key Facts

  • Net loss of $32.4M ($0.27/share) for Q3 2026 vs $26.0M ($0.35/share) in Q3 2025
  • Cash, cash equivalents, and short-term investments of $202M as of Sep 30, 2026, up from $145M at Dec 31, 2025
  • R&D expenses $26.1M vs $20.3M year-over-year; G&A $8.3M vs $7.7M
  • Grant revenue of $20K vs $209K in prior year quarter
  • Phase 1/2a bamzireotide navoxetan (VMT-α-NET) data presented at ESMO and NANETS; Cohort 4 enrollment completed
  • Lapemelanotide zapixetar (VMT01) monotherapy data in melanoma presented at SITC; 12 patients treated as of Oct 30, 2026
  • PSV359 received FDA Fast Track Designation for FAP-positive solitary fibrous tumors in October 2026
  • Clinical trial collaboration agreement with Merck to evaluate PSV359 in combination with Keytruda for certain lung and colorectal cancers
  • Cash runway expected to fund planned clinical milestones and operations into 2028

Financial Impact

Net loss of $32.4M in Q3 2026; cash position of $202M provides runway into 2028

net losscashR&D expenses

Risk Factors

  • Pre-revenue stage with no approved products; continued operating losses
  • Clinical trial risks across three early-stage programs
  • Dependence on successful regulatory interactions and future financing
  • Competition in radiopharmaceutical space

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3399027

Track record

34 reports on CATX

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +12.27% at T+5 after the Nov 5, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $0.9238 Now $0.9200 −0.41% settles Nov 18
  2. Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $0.9652 Now $0.9200 −4.68% settles Nov 17
  3. Nov 12, 20264d ago SC 13D/A Bearish 6/10 Entry $0.9431 to $0.9238 Now $0.9200 +2.45% ▲ +2.05% +0.13% vs SPY
  4. Nov 10, 20266d ago SC 13G Neutral 2/10 Entry $0.7864 to $0.8252 Now $0.9200 +16.99% ▲ +4.93% +3.62% vs SPY
  5. Nov 9, 20267d ago 8-K Neutral 4/10 No price data
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $0.7864 to $0.8252 Now $0.9200 +16.99% ▲ +4.93% +3.62% vs SPY
  7. Nov 6, 202610d ago 8-K Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
  8. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
  9. Nov 6, 202610d ago 8-K Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
  10. Nov 5, 202611d ago Press Release Bullish 6/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (10h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026